Aurora business Business Analysis

Aurora Expands Canadian (And Global) Footprint.

With the summer season (and recreational reform) fast approaching and the continued growth of the European medical market, Canadian LP Aurora has continued to power forward with another corporate acquisition. This time, the firm is medical cannabis firm MedReleaf (TSE:LEAF). The price? $3.2 billion in stock.

Aurora shareholders will now own 61% of MedReleaf.

The firm has also, of course, solidified its place as a global leader in the cannabis space with production capacity of over 570,000 kilos of cannabis a year.This purchase will absolutely ensure that the company is in a strong position

According to a statement by chief executive Terry Booth, “Our complementary assets, strategic synergies and strong market positioning will provide us with critical mass and an excellent product portfolio in preparation for the adult consumer use market in Canada.”

It also does a bit more than that.

With the German cultivation bid in what appears to be at least a three to six month delay, exports, including from Canada, are the only real way into Europe’s largest cannabis market. And Aurora, with it’s on the ground partner, Pedianos, isright in the middle of it. This purchase will absolutely ensure that the company is in a strong position as the next level of cannabis reform begins to unfold particularly in Europe.

Cannabis Is SO Expensive!

In fact, per this report just produced by one of the leading German public health insurers, Aurora, via Pedianos, and MedCann (the company that became both Spektrum Cannabis and bought out by Canopy Canada), appear to be the two Canadian LPs supplying the vast majority of all reimbursed medical cannabis to German patients. Further the vast majority of product is still coming from Canada – not the satellite grow or production facilities now being built in Portugal (Tilray), Denmark (Aurora and Canopy), Spain (Canopy) or anywhere else in Europe where legal cultivations are being established.

Techniker Krankenkasse report
“The Cannabis Report” produced by Techniker Krankenkasse (TK) and the University of Bremen, p.20

However, this also makes for an expensive product here in Germany, land of the generic drug (and where most of them can be bought by consumers, with a prescription, at a regular pharmacy for about $12). In fact, this report was produced in part to underscore the still-evolving medical position on the use of medical cannabis and its efficacy. This highlights how much Germany’s import policy is now costing even public insurers.

What is even more intriguing about the TK report is that the Germans are clearly moving into new research territory. Sure AIDS, chronic pain and muscle spasms (in particular MS) are conditions for which the drug is increasingly being prescribed, but so is ADD. And research studies are now mushrooming around the country.

The Germans have engaged on the medical cannabis efficacy question. And while it is still unclear what doses and of what kind of cannabinoid, have yet to be standardized into protocols, such conversations are well on their way.

And Aurora is also, of course, right in the middle of them.

Another Aurora Acquisition

Given the importance and size of the German market, in particular, it is also no surprise to see another strategic Aurora acquisition coming less than a week after the announcement of this report in Berlin. Specifically, Aurora has also just sunk another 1 million in an investment in CTT– an Ontario-based firm leading the development of thin film wafers that can provide dose specific, smoke free delivery of medical cannabinoids.

The Teutonic cannabis market is clearly in the company’s sights. Not to mention absolutely driving investment and positioning strategy both at home and abroad.

The post Aurora Expands Canadian (And Global) Footprint appeared first on Cannabis Industry Journal.

Aaron Biros

analysis analytics and Bureau for Public Health business cannabis cbd compliance consumer cultivation government growing industry law legal legalization legalize legislation license marijuana market medical medicine METRC Office of Medical Cannabis OMC platform product provider quality regulation regulations Regulatory retail safety sale seed software state system test The West Virginia Department of Health and Human Resources to trace traceability track Virginia West Virginia

Metrc Gets West Virginia Contract

activism analysis analytics ASA awareness brand branding Britain British business Business Analysis camapgin cannabidiol cannabis cbd communications company compliance consumer demographic digital engagement England English expert Federal government great growing industry Kaj Kajal law legal legalization legalize legislation license marijuana market marketing matter medical medicine NICE opportunities PR product Product Development progress public quality reform regulation regulations Regulatory relations retail Shah social media subject UK United Kingdom

The UK Cannabis Industry Needs New PR Strategies

adam jacques analysis analytical chemistry analytics business Business Analysis cannabinoid cannabis cbd Christian West clear CMGL Collaborative Laboratories for Environmental Analysis and Remediation cultivate cultivation Cultivation & Growing Curtis Mathes Grow Lights effects expression flavonoids genetics growing hemp horticultural indoor industry lab laboratories Laboratories & Analytics laboratory labs LC-QTOF-MS LED legalization legalize legislation license light lighting Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry manipulation marijuana market Matthew Spurlock phytochemical Phytochrome plant product Product Development Professor Kevin Schug Quality regulations research researcher researching Robert Manes science shimadzu spectrum terpenes test Testing University of Texas at Arlington University of Texas at El Paso UT Zacariah Hildenbrand ZED Therapeutics

UT-Arlington and UT-El Paso to Evaluate Phytochrome Manipulation in Hemp